Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program

Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III data in major depressive disorder later this quarter and ongoing Phase III work in generalized anxiety disorder.

Speaking at a conference, Roberts said the company is “really excited” for the Phase III Emerge study in major depressive disorder, or MDD, to read out later this quarter. She acknowledged that Definium does not have a standalone Phase II study in MDD, but said the company sees meaningful overlap between generalized anxiety disorder, or GAD, and MDD based on symptom scales.